The European Medicines Agency (EMA) and the European Organisation of Research and Treatment of Cancer (EORTC) are organising a multi-stakeholder workshop on soft tissue and bone sarcoma. It specifically addresses how we can develop new treatments in ultra-rare sarcomas, as a model for ultra-rare tumours.  
This workshop brings together academia, learned societies, patients, non-profit organisations, and medicines regulators to explore clinical and scientific aspects related to the development of medicines for ultra-rare cancers. The focus of the workshop is on methodological aspects of clinical studies (such as the use of master protocols), repurposing medicines, and the use of retrospective and real-world data, and prospective registries for further data collection. 

The aims of the workshop are to:

• discuss points to consider for developing rare cancer medicines using ultra-rare soft tissue and bone sarcomas as examples;
• facilitate interactions among relevant stakeholders aiming at international collaboration;
• establish a framework for regular meetings between the adult sarcoma community and EMA.